Robert Browne
Directeur Financier/CFO chez Viron Therapeutics, Inc.
Profil
Robert Browne is currently the Chief Financial Officer at Viron Therapeutics, Inc. He previously held the same position at Telesta Therapeutics, Inc. and Fennec Pharmaceuticals, Inc. Additionally, he was a Member of The Canadian Institute of Chartered Accountants.
Postes actifs de Robert Browne
| Sociétés | Poste | Début |
|---|---|---|
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Directeur Financier/CFO | - |
Anciens postes connus de Robert Browne
| Sociétés | Poste | Fin |
|---|---|---|
| TELESTA THERAPEUTICS INC | Directeur Financier/CFO | - |
| FENNEC PHARMACEUTICALS INC. | Directeur Financier/CFO | - |
The Canadian Institute of Chartered Accountants
 The Canadian Institute of Chartered Accountants Miscellaneous Commercial ServicesCommercial Services Canadian Institute of Chartered Accountants engages in the provision of accounting, auditing, tax, advisory, and professional services. The institute is headquartered in Toronto, Canada. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FENNEC PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
The Canadian Institute of Chartered Accountants
The Canadian Institute of Chartered Accountants Miscellaneous Commercial ServicesCommercial Services Canadian Institute of Chartered Accountants engages in the provision of accounting, auditing, tax, advisory, and professional services. The institute is headquartered in Toronto, Canada. | Commercial Services |
Telesta Therapeutics, Inc.
 Telesta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Telesta Therapeutics, Inc. is a biotechnology company, which focuses on the licensing/acquisition and development of transformational therapeutics for the treatment of serious human diseases, such as cancer, immune diseases, and targeted rare diseases. The company was founded by Graeme McRae in 1979 and is headquartered in Pointe-Claire, Canada. | Health Technology |
